Risk of Atrial Fibrillation and Stroke After Bariatric Surgery in Patients With Morbid Obesity With or Without Obstructive Sleep Apnea.

Background and Purpose: Weight loss in morbidly obese patients reduces atrial fibrillation (AF); however, it is unknown whether similar benefits are maintained in patients with obstructive sleep apnea (OSA). We sought to determine whether incident AF and stroke rates are affected by OSA after weight loss and to identify predictors of AF and stroke. Methods: Differences in laparoscopic adjustable gastric banding­induced weight loss on incident AF and stroke events in those with and without OSA in the entire and in propensity-matched cohorts were determined longitudinally, and independent predictors of AF and stroke were identified. Results: Of 827 morbidly obese patients who underwent laparoscopic adjustable gastric banding (mean age, 44±11 years; mean body mass index, 49±8 kg/m2), incident AF was documented in 4.96% and stroke in 5.44% of patients during a mean 6.0±3.2-year follow-up. Despite a similar reduction in body weight (19.6% and 21% in 3 years), new-onset AF was significantly higher in patients with OSA than without OSA in the entire (1.7% versus 0.5% per year; P<0.001) and propensity-matched cohorts. Incident stroke was higher in the OSA than in the non-OSA group (2.10% versus 0.47% per year; P<0.001), but only 20% of patients with stroke had documented AF. On multivariate analysis, OSA (hazard ratio, 2.88 [95% CI, 1.45­5.73]), age, and hypertension were independent predictors of new-onset AF, and OSA (hazard ratio, 5.84 [95% CI, 3.02­11.30]), depression, and body mass index were for stroke events. Conclusions: In morbidly obese patients who underwent laparoscopic adjustable gastric banding, despite similar weight loss, patients with OSA had a higher incidence of AF and stroke than patients without OSA. Both non-AF and AF-related factors were involved in increasing stroke risk. Further investigation is warranted into whether OSA treatment helps reduce AF or stroke events in this population.

Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly.

INTRODUCTION: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly used in the elderly with AF at high risk for stroke and bleeding and with comorbidities requiring polypharmacy, it is important to assess their safety and efficacy in this population. AREAS COVERED: We review changes in pharmacokinetics and pharmacodynamics observed with senescence and the effect on NOACs and drug and food interactions. We also provide an update on challenges related to NOAC use in situations that increases the risk for bleeding or require temporary discontinuation and address practical issues in the elderly AF patients managed on NOACs. Clinical studies and trials with cardiovascular outcomes reported from January 1990 to August 2020 were identified through the Medline database using PubMed, Cochrane Library, and EMBASE database. EXPERT OPINION: NOACs are highly effective in preventing stroke in AF patients with non-inferior or superior efficacy to warfarin, with reduced risk of major bleeding. However, in the older-elderly, evidence comes mainly from observational studies or extrapolation from studies in populations with minimal functional limitations or comorbidities. The high upfront cost and out-of-pocket expense for copayment or deductibles also limit the use of this effective therapy in a substantial number of patients. The cost reduction may further improve long-term use for NOACs in stroke prevention in elderly patients with AF.

Inappropriate shocks in patients with Fidelis® lead fractures: impact of remote monitoring and the lead integrity algorithm.

INTRODUCTION: The role of remote monitoring combined with lead integrity algorithm (LIA) in patients with Fidelis (Medtronic Inc., Minneapolis, MN, USA) lead fractures is not well defined. METHODS: We retrospectively identified patients with Fidelis lead fractures at our institution, documenting all pertinent data (remote monitoring use, clinical presentation, lead fracture diagnosis criteria). Patients were classified into subgroups based on the type of home monitoring and whether LIA was uploaded before lead fracture. Subgroups were compared based on delivery of inappropriate shocks (IS). RESULTS: A total of 131 patients (mean age 62 ± 16 years, 70% male, 69% primary prevention implants) were followed until lead fracture (average 32 ± 12 months). IS were delivered in 21% of patients (n = 11/52) with LIA versus 52% (n = 41/79) without LIA, P < 0.001. LIA significantly decreased the number of IS (2.1 ± 1.0 IS vs 7.9 ± 12 IS, P < 0.001) and significantly increased the number of patients diagnosed through audible alert (P < 0.001). Wireless monitoring significantly decreased the time interval to reprogram defibrillators OFF (mean 1.5 ± 1 days vs 15.6 ± 18 days with nonwireless CareLink [Medtronic Inc.] and 12.4 ± 20 days without CareLink, P < 0.001); 14% of patients with LIA and wireless monitoring combined received IS. Without LIA, 63% of patients with wireless monitoring received IS. CONCLUSION: This study confirms that LIA significantly decreases IS therapy in patients with Fidelis lead fractures. Wireless technology enhances LIA benefits by significantly shortening time to reprogram defibrillators. However, despite the "best scenario" of combining LIA and wireless monitoring, 14% of patients with lead fractures still get IS. Further refinements of detection algorithms are required to eliminate this significant clinical problem.